Drugging the bad "AKT-TOR" to overcome TKI-resistant lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) kinase inhibitors are crucial for lung cancer treatment.
• Acquired resistance, often due to the T790M mutation, limits the efficacy of these therapies.
• Activating EGFR mutations drive tumor growth but are susceptible to targeted inhibition.

Purpose of the Study:

• To investigate therapeutic strategies to overcome acquired resistance to EGFR kinase inhibitors in lung cancer.
• To evaluate the efficacy of combining an irreversible EGFR inhibitor with rapamycin in a resistant lung cancer model.

Main Methods:

• Utilized a mouse lung cancer model with activating EGFR mutations and the T790M resistance mutation.
• Administered an irreversible EGFR kinase inhibitor (HKI-272) alone and in combination with rapamycin.
• Monitored tumor regression and therapeutic response.

Main Results:

• The EGFR inhibitor HKI-272 showed limited activity as a monotherapy in the resistant lung cancer model.
• Combination therapy with HKI-272 and rapamycin resulted in rapid and significant tumor regression.
• This suggests a synergistic effect in overcoming EGFR-mediated drug resistance.

Conclusions:

• Combining EGFR kinase inhibitors with rapamycin is a promising strategy to overcome acquired resistance in EGFR-mutant lung cancer.
• This therapeutic approach could offer a new treatment option for patients who develop resistance to current therapies.
• Further clinical investigation is warranted to validate this combination strategy.